Myelofibrosis end points and self-evident truths
In this issue of Blood, Pemmaraju et al 1 identify, through TRANSFORM-1, both the promise and limits of combining navitoclax with ruxolitinib, sharpening a central challenge in myelofibrosis (MF) drug development: how best to measure meaningful clinical benefit.
Authors
- Pankit J. Vachhani (ORCID: https://orcid.org/0000-0001-9779-6217)
- Raajit K. Rampal (ORCID: https://orcid.org/0000-0002-0355-6368)
Institutions
- Memorial Sloan Kettering Cancer Center (US)
- University of Alabama at Birmingham (US)
Publication Details
- Journal
- Blood
- Published
- 2026-10-15
- DOI
- https://doi.org/10.1182/blood.2026035301
- Primary Topic
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Amgen
- Pfizer